About us Contacts Drug interactions: 390 212
Drug search by name

AccessPak for HIV PEP Expanded with Viracept and Carbamazepine Intravenous

Determining the interaction of AccessPak for HIV PEP Expanded with Viracept and Carbamazepine Intravenous and the possibility of their joint administration.

Check result:
AccessPak for HIV PEP Expanded with Viracept <> Carbamazepine Intravenous
Relevance: 23.03.2023 Reviewer: Shkutko P.M., M.D., in

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer:

CarBAMazepine may significantly reduce the blood levels of tenofovir from certain preparations, which may make it less effective in treating your condition. Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact, or you may need a dose adjustment or more frequent monitoring to safely use both medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Professional:

GENERALLY AVOID: Coadministration with inducers of P-glycoprotein (P-gp) may decrease the oral bioavailability and plasma concentrations of tenofovir alafenamide (TAF), which is a substrate of the efflux transporter. In 26 healthy study subjects, administration of TAF (25 mg once daily) with the P-gp inducer carbamazepine (300 mg twice daily) decreased TAF plasma concentration (Cmax) and systemic exposure (AUC) by an average of 57% and 55%, respectively, compared to TAF administered alone. It is not known if, and to what extent, tenofovir disoproxil fumarate (TDF), another prodrug of tenofovir, may interact with P-gp inducers. The interaction has not been studied with TDF, and no information is found in the labeling of various products containing TDF, although it has been reported to be a P-gp substrate also.

MANAGEMENT: Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiviral drug levels, concomitant use of tenofovir alafenamide fumarate with P-gp inducers is not recommended. Whether this also applies to tenofovir disoproxil fumarate has not been established.

References
  • "Product Information. Descovy (emtricitabine-tenofovir)." Gilead Sciences, Foster City, CA.
  • "Product Information. Vemlidy (tenofovir)." Gilead Sciences, Foster City, CA.
  • Cerner Multum, Inc. "Australian Product Information." O 0
  • Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
AccessPak for HIV PEP Expanded with Viracept

Generic Name: emtricitabine / nelfinavir / tenofovir

Brand name: AccessPak for HIV PEP Expanded with Viracept

Synonyms: n.a.

Carbamazepine Intravenous

Generic Name: carbamazepine

Brand name: Carbatrol, Epitol, Equetro, Tegretol, Tegretol XR, Tegretol, Tegretol XR

Synonyms: Carbamazepine, CarBAMazepine

In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.